Holen Sie sich die Stockscreener-App
0.7556
7.85%
-0.0644
Handel nachbörslich:
.77
0.0144
+1.91%
Schlusskurs vom Vortag:
$0.82
Offen:
$0.8
24-Stunden-Volumen:
167.13K
Relative Volume:
0.48
Marktkapitalisierung:
$4.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-5.85M
KGV:
-0.113
EPS:
-6.6877
Netto-Cashflow:
$-8.00M
1W Leistung:
-15.30%
1M Leistung:
-33.72%
6M Leistung:
-68.52%
1J Leistung:
-91.77%
1-Tages-Spanne:
$0.7327
$0.835
1-Wochen-Bereich:
$0.7327
$0.926
52-Wochen-Spanne:
$0.7327
$15.06
Alzamend Neuro Inc Stock (ALZN) Company Profile
Firmenname
Alzamend Neuro Inc
Sektor
Branche
Telefon
844-722-6333
Adresse
3500 LENOX RD. NE, ATLANTA
Vergleichen Sie ALZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
0.7556 | 4.43M | 0 | -5.85M | -8.00M | -6.6877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-01 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Aktie (ALZN) Neueste Nachrichten
Alzamend Neuro inks deal for equity securities sale By Investing.com - Investing.com South Africa
Alzamend Neuro inks deal for equity securities sale - Investing.com
Alzamend Neuro stock hits 52-week low at $0.81 amid sharp decline - Investing.com India
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital - The Manila Times
Can Alzamend's New Lithium Formulation Eliminate Monitoring Requirements? Phase II Trial Set for 2025 - StockTitan
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 - Yahoo Finance
EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels - AOL
Alzamend Neuro stock hits 52-week low at $1.05 amid challenges - Investing.com
Alzamend Neuro Announces Completion Of A Novel Head Coil By Tesla For Measuring Brain Structure Lithium Levels In Five Upcoming Phase Ii Clinical Trials At Massachusetts General Hospital - Marketscreener.com
Alzamend Neuro stock hits 52-week low at $1.05 amid challenges By Investing.com - Investing.com South Africa
Alzamend Neuro announces head coil for lithium studies By Investing.com - Investing.com South Africa
Alzamend Neuro announces head coil for lithium studies - Investing.com India
ALZNAlzamend Neuro Inc Latest Stock News & Market Updates - StockTitan
Alzamend Neuro announces completion of head coil by Tesla Dynamic Coils - TipRanks
Alzamend Neuro, Inc. Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital - Marketscreener.com
Alzamend Neuro stock hits 52-week low at $1.05 amid sharp decline - Investing.com Canada
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher - MSN
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Alzamend Neuro to Present at the Sequire Investor Summit - Business Wire
Alzamend Neuro CEO to Present Five Phase II Trial Plans at Sequire Investor Summit - StockTitan
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo - Business Wire
Alzamend Neuro (NASDAQ:ALZN) Price Target Cut to $32.00 by Analysts at Ascendiant Capital Markets - Defense World
Alzamend Neuro Reports Strong Financial Results and Clinical Program Updates - Defense World
Alzamend Neuro says net cash gained by financing activity $8.3M - Yahoo Finance
Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs - Business Wire
Alzamend Neuro Secures $25M Financing Deal, Advances Alzheimer's Drug Pipeline Amid Financial Turnaround - StockTitan
Alzamend Neuro Inc. (ALZN) reports earnings - Quartz
Alzamend Neuro stock hits 52-week low at $1.24 amid market challenges - Investing.com Nigeria
Alzamend reports promising results for brain-targeted lithium therapy - Investing.com India
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice - Business Wire
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential - Yahoo Finance
Alzamend Neuro stock hits 52-week low at $1.39 amid sharp decline - Investing.com
Alzamend Neuro sets trial dosage for AL001 lithium therapy - Alzheimer's News Today
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s - BioSpace
Alzamend Neuro advances Alzheimer's treatment with new lithium dose - Investing.com
Alzamend Neuro advances Alzheimer's treatment with new lithium dose By Investing.com - Investing.com South Africa
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's - Yahoo Finance
Alzamend Neuro Inc (ALZN) receives a Buy rating from Ascendiant Capital Markets - Knox Daily
Alzamend Neuro Inc (ALZN) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Alzamend Neuro Inc (ALZN-Q) QuotePress Release - The Globe and Mail
Alzamend Neuro regains Nasdaq compliance with equity rule By Investing.com - Investing.com UK
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards - StockTitan
Alzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42 - MSN
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference - Barchart
Finanzdaten der Alzamend Neuro Inc-Aktie (ALZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alzamend Neuro Inc-Aktie (ALZN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
Jul 31 '24 |
Buy |
3.74 |
25 |
93 |
77,193 |
| AULT MILTON C III | Director |
Apr 19 '24 |
Buy |
0.69 |
1,000 |
688 |
771,699 |
| AULT MILTON C III | Director |
Apr 01 '24 |
Buy |
0.91 |
334 |
304 |
770,699 |
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):